This expansion represents a significant milestone in our company's growth. By establishing a local presence in the U.S., we are strengthening our ability to provide exceptional service and support to our customers, ensuring that our innovative self-sampling solutions are accessible to more people.

Establishing Capitainer Inc. is a strategic investment that aligns with our long-term goals of scaling up operations in key regions. This will allow us to better serve our existing customers while also positioning us to meet increasing demand for self-sampling solutions across North America.

With our new product, Capitainer is meeting a since long existed demand on the market, by providing a solution to enable at-home collection of plasma

The new sampling card automates the entire collection process, making it the ultimate at-home sampling product for dried plasma-like material

Many customers have requested a ready-made solution to avoid handling the registration processes for their kits. By offering a complete solution, we can better meet our customers’ needs and expectations. This allows them to reach their patients more efficiently and introduce Capitainer as a solution for all groups who can benefit from self-sampling, so patients don’t need to visit a healthcare facility for a venous blood sample.

We are excited to welcome Kristina Thomsen Hall to our executive team. Her extensive experience and proven track record in financial management make her an ideal fit for Capitainer as we continue to execute our strategic plan and drive long-term value.

It is an honor to join Labquality's board. The mission for Labquality aligns with my career-long aspiration to support patients and healthcare providers with new, high-quality solutions. I look forward to contributing to our efforts to promote healthcare quality globally, a goal that resonates with Capitainer's vision of equal access to healthcare diagnostics for all.

This research demonstrates the potential of self-sampling and Capitainer's blood sampling solution. It offers the opportunity to conduct large scientific studies more efficiently and with the participants in focus. We are very pleased with the collaboration with Chalmers and that our products can contribute to new knowledge and hopefully preventive measures for major public health issues.

We are delighted to collaborate with Lasec®, whose expertise and extensive network in South Africa and beyond are crucial to our expansion strategy. This partnership is a major step towards our commitment to enhancing healthcare standards across Africa with our innovative products.

Our investment in the sales organization is strategically important at a time when the company sees a strong increase in interest based on the implementation projects that are now underway. Mikael Ström, former Business Development Manager, takes the role of Business Development Director and the recruitment of Ylva as Sales and Distribution Manager means that we increase the pace now and in the future within our sales organization.

This strategic capital boost allows us to fast-track our expansion, with a particular focus on enhancing our presence in the USA, where we recently inaugurated our own laboratory. We are actively engaging in major sales initiatives in several countries across Europe and the USA. The steadfast support from our shareholders and Sciety significantly drives and accelerates our ongoing growth.

It's highly encouraging to see a Swedish lab advancing home testing while ensuring the quality of analysis remains high for those requiring TSH and fT4 measurements. This development paves the way for numerous possibilities to simplify the process for individuals and to discover efficient, sustainable healthcare practices.

We are very happy to welcome Louise and Andreas to our board. Their backgrounds and proven track records in healthcare, technology, and strategic investments will be instrumental in guiding Capitainer through our next phase of growth. The expertise they bring is a testament to their individual accomplishments and aligns perfectly with our mission to revolutionize the diagnostics industry through innovation and leadership.

Receiving an investment from an industry-leading venture capital company like We Venture Capital is a significant seal of approval. This investment is a testament to our innovative approach in self-sampling solutions and also a strategic alliance that will propel our efforts in enhancing product validation, expanding our market reach, and establishing a stronghold in the industry.

The demand for ready-made protocols for analysis on existing instruments at the laboratories is great. Johan's knowledge greatly strengthens Capitainer's ability to develop these protocols and to support laboratories in their own method development, which will accelerate the use of our technology in clinical diagnostics.

This marks a significant step in bringing our advanced dried blood sampling devices and expertise to the U.S. healthcare sector. Our new laboratory will use the Capitainer platform to validate various applications, making it simpler for our laboratory partners to set up services based on Capitainer products.

These patents reinforce our strategic position, facilitating Capitainer's expansion in the US market. The recognition from the United States Patent Office is a testament to the technological advancements we've achieved. This enables us to extend our advanced solutions to a broader range of healthcare providers and researchers.

We are very proud that our sampling solution has formed the basis for this important research. Knowing that our product has been crucial in collecting data and deriving conclusions that make a significant difference in the care of our elderly and most vulnerable citizens feels immensely meaningful.

Tests and analyses have been developed for and from our sample material. The fact that Capitainer's self-sampling card serves as the foundation for this groundbreaking project is a clear indication of our pivotal role in advancing highly sensitive and robust diagnostic solutions for individualized monitoring.

The proof that Capitainer’s solution enables samples to be taken at home with the same quality as if taken by a nurse in the hospital, reinforces our belief and mission that Capitainer's products have a given place in the fast-growing market for at-home sampling solutions. We firmly believe that Capitainer's product line is strategically positioned within this expansive landscape.

We’re extremely pleased to be able to welcome Mathias Karlsson to the Capitainer team as our new Chief Medical Officer. His extensive knowledge and expertise within healthcare, diagnostics and medical technology, combined with his experience as an entrepreneur, are exceedingly valuable to Capitainer’s future development.

Thanks to the continued support from Sciety, we are able to accelerate our growth and expand our production capacity. Their expertise in life science combined with industry connections will be valuable for Capitainer as we continue to advance. We are confident that our self-sampling technology will become a game-changer in the healthcare industry, providing patients with greater convenience and accessibility while ensuring precise results.

We are delighted to welcome Yvonne Zar Berglund as our new Sales & Distribution Manager. With her extensive knowledge in life science and expertise in sales and distribution, Yvonne will be a valuable asset as we continue to grow and implement our commercialisation strategy going forward.

The launch of this fully automated sample handler marks a significant breakthrough in the commercialisation of Capitainer and means that we can now implement the company’s self-sampling solutions on a large scale. We have worked hard to reduce laboratory handling times and make our products easier for laboratory staff to work with. This strengthens our position as a solution for large-scale screening and diagnostics.

Remote microsampling in patients’ homes will reduce the patient burden and permit the inclusion of underserved populations to improve patient diversity. Home sampling will also enable more frequent data collection that will improve drug development decisions.

Capitainer’s products, delivering high precision accuracy blood and plasma sampling, are the missing link to enable a broader implementation of personalised medicine, proteomics, and clinical monitoring in today’s healthcare.

This means more laboratories will have the opportunity to analyse our samples.

Martin’s knowledge and experience from clinical diagnostics, combined with expertise from innovative healthcare providers, implementing new ideas and clinical work, makes him a perfect match for Capitainer.